Lucerastat
| Code | Size | Price |
|---|
| TAR-T32923-50mg | 50mg | £870.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T32923-100mg | 100mg | £1,484.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lucerastat is a very effective and selective α-gal A (α-D-galactosidase) inhibitor for the treatment of lipid storage diseases and Fabry disease.
CAS:
141206-42-0
Formula:
C10H21NO4
Molecular Weight:
219.281
Purity:
0.98
SMILES:
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO
References
1. Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barrag?n T, Hirano Y, Yura K, Yu L, Ninomiya H, Garc?a-Moreno MI, Sakakibara Y, Ohno K, Nanba E, Ortiz Mellet C, Garc?a Fern?ndez JM, Suzuki Y. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32. doi: 10.1038/mt.2012.263. Epub 2013 Jan 22. PubMed PMID: 23337983; PubMed Central PMCID: PMC3589148.
2. Kato T, Muraoka M, Hatanaka K. Novel method for chase analysis of oligosaccharide metabolic error caused by xenobiotics. Anal Biochem. 2010 Oct 1;405(1):103-8. doi: 10.1016/j.ab.2010.06.002. Epub 2010 Jun 4. PubMed PMID: 20570645.
3. Kato A, Yamashita Y, Nakagawa S, Koike Y, Adachi I, Hollinshead J, Nash RJ, Ikeda K, Asano N. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. doi: 10.1016/j.bmc.2010.04.048. Epub 2010 Apr 21. PubMed PMID: 20457528.
4. Gerrard G, Butters TD, Ganeshaguru K, Mehta AB. Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity. Eur J Pharmacol. 2009 May 1;609(1-3):34-9. doi: 10.1016/j.ejphar.2009.03.018. Epub 2009 Mar 12. PubMed PMID: 19285492.